ソラフェニブ誘発の心臓毒性のメカニズム:ERストレスはATF3のアップレギュレーションを誘導し,NDUFS1の発現とミトコンドリア機能障害のダウンレギュレーションにつながります.
PubMedで要約を見る
まとめ
この要約は機械生成です。ソラフェニブは,エンドプラズマの網膜のストレスを誘発し,PERK/ eIF2α/ ATF4経路を活性化することによって,心臓毒性を引き起こします. ATF3をターゲットにすることで,この心臓損傷を防ぐことができます.
科学分野
- 心臓病科
- 分子生物学
- 薬理学について
背景
- チロシンキナーゼ阻害剤 (TKI) であるソラフェニブは心臓毒性に関連しています.
- ソラフェニブによる心臓毒性の分子メカニズムは完全に理解されていません.
- この研究では,内プラズマ網膜 (ER) ストレスに焦点を当てて,心臓細胞に対するソラフェニブの効果を調査しています.
研究 の 目的
- ソラフェニブによる心臓毒性の 分子基礎を解明する
- ソラフェニブの心臓毒性におけるPERK-eIF2α-ATF4シグナル伝達経路の役割を調べる.
- ソラフェニブによる心臓損傷を緩和するための潜在的な治療標的を特定する.
主な方法
- In vivoラットモデルとH9C2細胞アッセイが使用された.
- トランスクリプトミック,プロテオミック,生化学的検証技術が採用された.
- ERストレス阻害とATF3サイレンスが調査されました.
主要な成果
- ソラフェニブは心筋細胞にERストレスを誘発し,PERK- eIF2α- ATF4経路を活性化し,ミトコンドリア損傷とアポトーシスを引き起こします.
- ERストレス阻害剤GSK2606414はこれらの効果を緩和しました.
- 活性化トランスクリプション因子3 (ATF3) は,その静止がミトコンドリア機能を部分的に回復させる重要な媒介体として特定されました.
結論
- PERK/eIF2α/ATF4/ATF3/NDUFS1を含むシグナリングカスケードは,ソラフェニブ媒介の心臓毒性において極めて重要です.
- ATF3はソラフェニブによるミトコンドリア機能障害において重要な役割を果たします.
- ソラフェニブの心毒性を予防するための治療戦略として,ATF3を調節することが可能である.
関連する概念動画
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

